Clinical Trials · NCT07616401
MicroRNA and Markers and Therapeutic Response to Romosozumab and Abaloparatide in Postmenopausal Osteoporosis
- Phase
- N/A
- Recruitment status
- Recruiting
- Sponsor
- Istituto Auxologico Italiano
- Enrollment
- 42
- Start date
- Aug 2025
- Locations
- 2 sites, Italy
- Primary endpoint
- miRNA expression profile